RBC Capital analyst George Hill raised his price target on Cardinal Health to $60 on slight adjustment of his rolled-forward model related to the timing of the company's earnings. The analyst keeps his Sector Perform rating however and warns that operational issues in its Medical business will weight on the results while its brand drug business also proves to be "optimistic". Hill further contends that Cardinal Health's brand drug pricing increase may come in below expectations, lowering FY19 EPS view to $4.79 from $4.87 which is below its current guidance range of $4.90-$5.15.